N/A
N=5
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
Papillomavirus Infections · Warts · Condylomata Acuminata · Epidermodysplasia Verruciformis
Bottom Line
View on ClinicalTrials.gov: NCT00973856 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: Difference in % Reduction in Wart Size Between Product A and Product B at Each Timepoint
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- PURELL VF481 (Other); Placebo Solution (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cleveland Clinic Akron General
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference in % Reduction in Wart Size Between Product A and Product B at Each Timepoint |
— | — |
| SECONDARY Change in Size of Warts Treated by Each Product at Each Time Point. |
— | — |
Summary
The objective is to conduct a pilot study to determine the effectiveness of PURELL VF481 to treat warts located on the hands.
Eligibility Criteria
Inclusion Criteria
- Patients with 2+ warts being seen at a Dermatologist's office
- 2 or more warts on the hands that are located at least 1 cm apart or on separate fingers
- Warts must have been present for at least 2 months
- Wart size must be between 2 mm-15 mm in diameter
- Participants must be in good general health
- Participants must be able to speak and read in English.
- Participant must be able to read and sign participant instruction sheet, and informed consent and authorization.
- Subjects must be able to understand and execute the instructions presented in pictorial form.
Exclusion Criteria
- Pregnancy (Patients will be asked to verify using criteria of contraception, menstrual cycle, and pregnancy test, if necessary).
- Treatment of warts with other methods such as salicylic acid, etc., in the past 14 days.
- Known allergies to common topical antimicrobials or the individual ingredients in either test product.
- Participation in a clinical study in the past 7 days or participation in another clinical study
- Unwillingness to perform requirements of the study
- Any medical condition that should preclude participation in the study, at the discretion of the physician
- Missed ≥ 6 of the treatments in a 4 week study period
Data sourced from ClinicalTrials.gov (NCT00973856). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.